| abstract |
The present disclosure provides materials and methods for reducing inflammation in the gut and/or joints of a patient, and optionally treating rheumatoid arthritis (RA) and other inflammatory or autoimmune diseases, in a patient. The present disclosure provides such methods based, in part, on the susceptibility of the patient's gut microbiome to methotrexate (MTX) as described herein. |